Hepatic Failure and Hepatorenal Syndrome with Tarceva (Dec. 2008)

OSI Pharmaceuticals and Genentech are alerting healthcare professionals about hepatic failure and hepatorenal syndrome with the use of Tarceva (erlotinib), particularly in patient with baseline hepatic impairment. Tarceva is approved to treat certain patients with lung or pancreatic cancer.

Patients with hepatic impairment who are treated with Tarceva should be closely monitored during therapy. Treatment should be interrupted or discontinued if patients have severe changes in liver function. Tarceva should be used with extra caution in patients with total bilirubin greater than three times the upper limit of normal.

Category:

Education

Tags:

• Hepatic
• Failure
• Hepatorenal
• Syndrome
• Tarceva
• FDA
• Lung
• Pancreatic
• Cancer
• Liver
• Function
• Patient
• Safety